Weekly Dose-Dense Chemotherapy Does Not Improve PFS in First-Line Treatment for Epithelial Ovarian Cancer
ICON8 results show no improvement in progression-free survival compared with standard 3-weekly regimen in predominantly European population
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
Fostamatinib Received a Positive Opinion from the EMA for the Treatment of Primary Immune Thrombocytopenia
Fostamatinib blocks spleen tyrosine kinase.
People with Mental Illness Receive Less Cancer Screening
Findings from the systematic review and comparative meta-analysis
Randomised Trial of Supplemental MRI Screening in Women with Extremely Dense Breast Tissue
The results from the DENSE study
EMA Recommends Granting a Conditional Marketing Authorisation for Polatuzumab Vedotin
It is intended for the treatment of relapsed/refractory DLBCL in combination with bendamustine and rituximab
First-line Treatment with Osimertinib Associated with Longer OS in EGFR Mutation–positive Advanced NSCLC
Osimertinib provides longer overall survival than a comparator EGFR tyrosine kinase inhibitor in EGFR mutation–positive, advanced non-small cell lung cancer
FDA Approves Acalabrutinib for CLL and SLL
Evidence for efficacy is based on the results from the ELEVATE-TN and ASCEND studies
EMA Recommends Extension of Indications for Lenalidomide
New indication concerns combination therapy with rituximab for previously treated follicular lymphoma
Atezolizumab in Combination with Bevacizumab Provides Superior Outcome Compared with Sorafenib in Unresectable HCC
IMbrave150 results may be practice changing in the first-line setting for unresectable hepatocelluar carcinoma
Unique Factors Impact Outcome in AYA Patients with Cancer
Characteristics of cancer in adolescents and young adults are defined and suggestions provided to improve survival
Exploratory Analysis of FIRE-3 According CRC Consensus Molecular Subgroups
Molecular classification provides deeper insights into biology of colorectal cancer, but at present time with no impact on clinical decision-making
Adding Isatuximab to Pomalidomide and Low-Dose Dexamethasone Improves PFS in Relapsed and Refractory Multiple Myeloma
Important advance in the management of patients who represent an otherwise unmet medical need